DK4255563T3 - 5´-o-phenylacetyluridin og terapeutisk anvendelse - Google Patents

5´-o-phenylacetyluridin og terapeutisk anvendelse

Info

Publication number
DK4255563T3
DK4255563T3 DK21901291.1T DK21901291T DK4255563T3 DK 4255563 T3 DK4255563 T3 DK 4255563T3 DK 21901291 T DK21901291 T DK 21901291T DK 4255563 T3 DK4255563 T3 DK 4255563T3
Authority
DK
Denmark
Prior art keywords
phenylacetyluridine
therapeutic use
therapeutic
Prior art date
Application number
DK21901291.1T
Other languages
English (en)
Inventor
Garcia Rolando Alejandro Garcia
Joel A Saydoff
Borstel Reid Warren Von
David Michael Simpson
Original Assignee
Pharma Cinq Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Cinq Llc filed Critical Pharma Cinq Llc
Application granted granted Critical
Publication of DK4255563T3 publication Critical patent/DK4255563T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
DK21901291.1T 2020-12-01 2021-11-30 5´-o-phenylacetyluridin og terapeutisk anvendelse DK4255563T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063119764P 2020-12-01 2020-12-01
PCT/US2021/061053 WO2022119784A1 (en) 2020-12-01 2021-11-30 5'-o-phenylacetyluridine and therapeutic use

Publications (1)

Publication Number Publication Date
DK4255563T3 true DK4255563T3 (da) 2026-03-16

Family

ID=81854225

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21901291.1T DK4255563T3 (da) 2020-12-01 2021-11-30 5´-o-phenylacetyluridin og terapeutisk anvendelse

Country Status (21)

Country Link
US (1) US12630580B2 (da)
EP (2) EP4255563B1 (da)
JP (1) JP7860983B2 (da)
KR (1) KR20230112118A (da)
CN (1) CN116782912A (da)
AU (1) AU2021391411A1 (da)
BR (1) BR112023010517A2 (da)
CA (1) CA3199559A1 (da)
DK (1) DK4255563T3 (da)
ES (1) ES3065683T3 (da)
FI (1) FI4255563T3 (da)
HR (1) HRP20260370T1 (da)
IL (1) IL303100A (da)
LT (1) LT4255563T (da)
MX (1) MX2023006343A (da)
PL (1) PL4255563T3 (da)
PT (1) PT4255563T (da)
RS (1) RS67894B1 (da)
SI (1) SI4255563T1 (da)
SM (1) SMT202600137T1 (da)
WO (1) WO2022119784A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3060948T3 (en) 2020-09-14 2026-03-30 Pharma Cinq Llc 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
DK4255563T3 (da) 2020-12-01 2026-03-16 Pharma Cinq Llc 5´-o-phenylacetyluridin og terapeutisk anvendelse
EP4294405A4 (en) 2021-02-21 2025-01-29 Pharma Cinq, LLC COMPOSITIONS AND COMPOUNDS FOR CO-ADMINISTRATION OF URIDINE AND KETOLEUCINE
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992534A (en) 1987-08-12 1991-02-12 Otsuka Pharmaceutical Co., Ltd. 3'-O-,5'-O-derivatives of 2'-deoxy-5-fluorouridine
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
JP2526414B2 (ja) * 1994-05-20 1996-08-21 工業技術院長 制ガン剤エステル化合物及びその製造方法
CN101066276A (zh) * 1994-07-01 2007-11-07 威尔斯塔特医疗公司 用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
BR0008447A (pt) * 1999-02-23 2002-01-15 Univ California Métodos de tratamento de distúrbios mitocondriais
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
WO2005094236A2 (en) 2003-11-07 2005-10-13 Henry M. Jackson Foundation Activation of hypoxia-inducible gene expression
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
PT2319581E (pt) * 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
KR100818202B1 (ko) 2006-12-22 2008-03-31 한국과학기술원 미생물의 성장에 필수적인 대사산물의 스크리닝 방법
MX2014000419A (es) 2011-07-15 2014-09-22 Nusirt Sciences Inc Composicones y metodos para modular trayectorias metabolicas.
HUE036133T2 (hu) * 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére
PL2968385T3 (pl) 2013-03-13 2019-05-31 Univ Tufts Pochodne nukleozydów urydynowych, kompozycje i sposoby zastosowania
US20170209476A1 (en) 2014-08-19 2017-07-27 Wellstat Therapeutics Corporation Treatment of Glycosylation Deficiency Diseases
US20180318381A1 (en) 2015-10-23 2018-11-08 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Methods of Treatment of Rhabdomyolysis
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
IL276236B2 (en) 2018-02-01 2025-12-01 Wellstat Therapeutics Corp Compositions and devices comprising uridine and the d enantiomer of beta-hydroxybutyrate and a cationic counterion
ES3060948T3 (en) 2020-09-14 2026-03-30 Pharma Cinq Llc 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
CN116437930A (zh) * 2020-10-30 2023-07-14 上海岸阔医药科技有限公司 尿苷衍生物在制备药物中的应用
DK4255563T3 (da) 2020-12-01 2026-03-16 Pharma Cinq Llc 5´-o-phenylacetyluridin og terapeutisk anvendelse
EP4294405A4 (en) 2021-02-21 2025-01-29 Pharma Cinq, LLC COMPOSITIONS AND COMPOUNDS FOR CO-ADMINISTRATION OF URIDINE AND KETOLEUCINE

Also Published As

Publication number Publication date
JP7860983B2 (ja) 2026-05-18
CA3199559A1 (en) 2022-06-09
WO2022119784A1 (en) 2022-06-09
PT4255563T (pt) 2026-03-24
PL4255563T3 (pl) 2026-04-20
RS67894B1 (sr) 2026-04-30
CN116782912A (zh) 2023-09-19
FI4255563T3 (fi) 2026-03-13
JP2023551467A (ja) 2023-12-08
EP4711007A2 (en) 2026-03-18
BR112023010517A2 (pt) 2024-02-06
SI4255563T1 (sl) 2026-05-29
AU2021391411A9 (en) 2024-07-18
HRP20260370T1 (hr) 2026-05-22
MX2023006343A (es) 2023-06-12
US20230416292A1 (en) 2023-12-28
EP4711007A3 (en) 2026-04-01
EP4255563B1 (en) 2025-12-31
ES3065683T3 (en) 2026-05-07
AU2021391411A1 (en) 2023-07-20
IL303100A (en) 2023-07-01
EP4255563A4 (en) 2024-09-11
KR20230112118A (ko) 2023-07-26
US12630580B2 (en) 2026-05-19
LT4255563T (lt) 2026-04-10
EP4255563A1 (en) 2023-10-11
SMT202600137T1 (it) 2026-05-12

Similar Documents

Publication Publication Date Title
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
EP4259157A4 (en) DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES
IL280483A (en) Muscle targeting complexes and uses thereof for treating pompe disease
DK4161935T3 (da) Brm-målrettende forbindelser og tilhørende anvendelsesmetoder
PL3661954T3 (pl) Muteiny interleukiny 21 i sposoby leczenia
EP4262883C0 (en) PEG LIPIDS AND LIPID NANOPARTICLES
EP4357781B1 (en) SARS-CoV-2 Immunological Assay Method and Immunological Assay Kit
DK4196479T5 (da) Substituerede pyridotriazinforbindelser og anvendelser deraf
DK3922266T3 (da) Toll-like-receptor-7- eller -8-agonist-kolesterolkompleks og anvendelse deraf
ES3065683T3 (en) 5'-o-phenylacetyluridine and therapeutic use
DK3986419T3 (da) Boronsyre-derivater og terapeutiske anvendelser heraf
DK3710485T3 (da) Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder
GB202108572D0 (en) Therapeutic compounds and their use
EP3878380A4 (en) Clip unit and endoscope clip
EP4419555A4 (en) P40 VARIANTS OF HUMAN IL-12 AND THEIR USES
DK3618848T3 (da) Biologisk aktive komplekser og terapeutiske anvendelser deraf
DK3919498T6 (da) Pyrrolopyrimidinderivat og anvendelse deraf
DK3892621T3 (da) Haloallylaminforbindelser og anvendelse deraf
GB202019475D0 (en) Therapeutic compounds and their use
EP4416294A4 (en) STEREOCILINE PROMOTERS AND THEIR USES
DK4429686T3 (da) Postbiotiske sammensætninger omfattende b. longum cect- 7347 og l. rhamnosus cect- 8361 og terapeutiske anvendelser deraf
IL313081A (en) New HDAC inhibitors and their medical use
EP4034113A4 (en) THERAPEUTIC FORMULATIONS AND THEIR USES
DK3937948T3 (da) Phytoecdysoner og derivater deraf til anvendelse i behandlingen af neuromuskulære sygdomme
DK3946260T3 (da) Pregabalinformuleringer og anvendelse deraf